Incannex Healthcare (ASX:IHL) has attracted market attention due to its lead drug candidate, IHL-42X, which is being developed for the treatment of obstructive sleep apnea (OSA). The company announced positive results from its Phase 2 clinical trial in early 2025, showing statistically significant reductions in the apnea-hypopnea index (AHI) compared to placebo.
According to the company's announcements, IHL-42X combines dronabinol and acetazolamide. In the Phase 2 trial, the highest dose tested reduced AHI by an average of 50% from baseline, with a favorable safety profile. The company is preparing to initiate Phase 3 trials, with a meeting with the U.S. Food and Drug Administration (FDA) expected in 2026.
Incannex has also been progressing its other pipeline assets, including treatments for anxiety and inflammatory conditions. The company's focus on OSA, a condition affecting millions worldwide, has positioned it as a potential player in the sleep medicine market.
As of August 2026, Incannex continues to trade on the ASX, with investors closely watching for updates on the Phase 3 trial design and regulatory interactions. The company has stated that it expects to provide further guidance on the trial timeline in the coming months.
